About Bioasis technologies, inc.
Bioasis Technologies, Inc. is a biopharmaceutical company that is committed to providing hope to patients who are suffering from neurological diseases and disorders. The company's innovative science focuses on transporting medicines across the blood-brain barrier, which has opened up a path to hundreds of previously untreatable diseases of the central nervous system.
The blood-brain barrier (BBB) is a highly selective membrane that separates the circulating blood from the brain extracellular fluid in the central nervous system (CNS). It plays an essential role in maintaining homeostasis within the CNS by preventing harmful substances from entering it. However, this also makes it difficult for drugs to reach their target sites within the brain, making it challenging for researchers and clinicians to develop effective treatments for neurological disorders.
Bioasis Technologies has developed a proprietary technology platform called Transcend™ that enables efficient transport of therapeutic molecules across the BBB. This breakthrough technology has significant potential in treating various CNS disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and brain cancer.
The company's lead product candidate is xB3-001, which targets HER2-positive breast cancer brain metastases. This condition affects approximately 30% of women with advanced breast cancer and currently has no effective treatment options available. Bioasis' Transcend™ technology allows xB3-001 to cross over into the brain where it can target HER2-positive cells effectively.
In addition to its lead product candidate xB3-001, Bioasis Technologies also has several other programs in development targeting different CNS disorders such as lysosomal storage diseases and neurodegenerative conditions like Huntington's disease.
Bioasis' team comprises experienced scientists and executives who have extensive knowledge in drug development and commercialization. They are dedicated to advancing their pipeline of products through rigorous research and clinical trials while ensuring patient safety remains at the forefront of their efforts.
The company operates under strict ethical standards with transparency being a core value. Bioasis Technologies is committed to working with patients, healthcare providers, and regulatory agencies to ensure that their products are safe and effective.
In conclusion, Bioasis Technologies is a biopharmaceutical company that has developed a breakthrough technology platform called Transcend™ that enables efficient transport of therapeutic molecules across the BBB. The company's lead product candidate xB3-001 targets HER2-positive breast cancer brain metastases and has significant potential in treating various CNS disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and brain cancer. With its experienced team of scientists and executives dedicated to advancing their pipeline of products through rigorous research and clinical trials while ensuring patient safety remains at the forefront of their efforts, Bioasis Technologies is poised to make a significant impact in the field of neuroscience.
bioasis.us
